

Company Announcement

1 March 2010

Novo Nordisk A/S – Share repurchase programme

On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.

Since the announcement as of 22 February 2010, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	1,305,000		496,879,259
22 February 2010	85,000	396.5120	33,703,520
23 February 2010	155,000	389.5312	60,377,336
24 February 2010	91,000	391.8990	35,662,809
25 February 2010	90,000	387.4210	34,867,890
26 February 2010	85,000	386.0500	32,814,250
Accumulated under the programme	1,811,000		694,305,064

With the transactions stated above, Novo Nordisk owns a total of 32,082,298 treasury shares, corresponding to 5.2% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone

therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:

Elin K Hansen
Tel: (+45) 4442 3450
ekh@novonordisk.com

In North America:

Sean Clements
Tel: (+1) 609 514 8316
secl@novonordisk.com

Investors:

Klaus Bülow Davidsen
Tel: (+45) 4442 3176
klda@novonordisk.com

Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com

In North America:

Hans Rommer
Tel: (+1) 609 919 7937
hrrmm@novonordisk.com